Comerica Bank Has $4.52 Million Stake in DaVita Inc. $DVA

Comerica Bank grew its position in shares of DaVita Inc. (NYSE:DVA) by 13.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 39,756 shares of the company’s stock after buying an additional 4,563 shares during the quarter. Comerica Bank’s holdings in DaVita were worth $4,517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in DVA. Elevation Wealth Partners LLC lifted its holdings in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita during the 2nd quarter valued at about $43,000. iSAM Funds UK Ltd acquired a new stake in shares of DaVita during the 3rd quarter valued at about $46,000. Stance Capital LLC bought a new position in shares of DaVita in the 3rd quarter valued at approximately $47,000. Finally, SJS Investment Consulting Inc. raised its stake in shares of DaVita by 3,091.7% in the 3rd quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock valued at $51,000 after acquiring an additional 371 shares in the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. UBS Group raised their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Truist Financial set a $158.00 price objective on DaVita in a research note on Thursday, February 5th. Barclays raised their price objective on DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $155.80.

DaVita Stock Down 2.2%

Shares of NYSE DVA opened at $151.80 on Friday. The business’s 50 day moving average is $151.18 and its two-hundred day moving average is $131.48. The company has a market cap of $10.14 billion, a P/E ratio of 15.32, a P/E/G ratio of 0.53 and a beta of 0.84. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $159.42.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. The company had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Sell-side analysts expect that DaVita Inc. will post 14.16 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.